Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

AnaptysBio, Inc. - Common Stock (NQ:ANAB)

48.20 +0.07 (+0.16%)
Streaming Delayed Price Updated: 10:54 AM EST, Jan 14, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about AnaptysBio, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
News headline image
Analyst Expectations For AnaptysBio's Future ↗
 
Via Benzinga
News headline image
AnaptysBio (ANAB) Q2 Revenue Jumps 103% ↗
Via The Motley Fool
Topics Intellectual Property
News headline image
Anaptys Announces Second Quarter 2025 Financial Results and Provides Business Update
From AnaptysBio, Inc.
Via GlobeNewswire
News headline image
Analyst Expectations For AnaptysBio's Future ↗
 
Via Benzinga
News headline image
AnaptysBio's Arthritis Drug Matches Top Therapies In Phase 2 Trial, Analyst Sees Turning Point ↗
Rosnilimab met key RA trial goals, with sustained clinical responses and safety benefits, prompting an analyst upgrade and price target hike to $38. 
Via Benzinga
News headline image
Beyond The Numbers: 5 Analysts Discuss AnaptysBio Stock ↗
 
Via Benzinga
News headline image
Where AnaptysBio Stands With Analysts ↗
 
Via Benzinga
News headline image
Analyst Expectations For AnaptysBio's Future ↗
 
Via Benzinga
News headline image
Crude Oil Falls Over 1%; ISM Services PMI Tumbles In May ↗
 
Via Benzinga
News headline image
This Snowflake Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday ↗
 
Via Benzinga
News headline image
AnaptysBio Stock Jumps On Promising Rheumatoid Arthritis Drug Readout; Retail Traders Brace For Potential Offering ↗
The company reported successful mid-stage results for its rheumatoid arthritis drug rosnilimab, which matched the efficacy of JAK inhibitors with fewer side effects. 
Via Stocktwits
News headline image
Anaptys Announces Positive Rosnilimab Data Updated Through Six Months in Robust Phase 2b Trial in RA
From AnaptysBio, Inc.
Via GlobeNewswire
News headline image
Heico, Monro, Abercrombie & Fitch, Joby Aviation And Other Big Stocks Moving Higher On Wednesday ↗
 
Via Benzinga
News headline image
Anaptys to Announce Updated Data from Phase 2b Trial of Rosnilimab, a PD-1 Depleter and Agonist, for Rheumatoid Arthritis on June 3, 2025
From AnaptysBio, Inc.
Via GlobeNewswire
News headline image
Forecasting The Future: 6 Analyst Projections For AnaptysBio ↗
 
Via Benzinga
News headline image
Anaptys Announces First Quarter 2025 Financial Results and Provides Business Update
From AnaptysBio, Inc.
Via GlobeNewswire
News headline image
Bright Peak Therapeutics Appoints John Schmid to its Board of Directors
From Bright Peak Therapeutics, Inc.
Via GlobeNewswire
News headline image
Crude Oil Gains 1%; US Composite PMI Surges In March ↗
 
Via Benzinga
News headline image
Intuitive Machines Posts Q4 Results, Joins Tesla, AnaptysBio, Coherent And Other Big Stocks Moving Higher On Monday ↗
 
Via Benzinga
News headline image
Anaptys Announces Stock Repurchase Plan
From AnaptysBio, Inc.
Via GlobeNewswire
News headline image
UiPath Posts Weak Revenue, Joins SentinelOne, American Eagle And Other Big Stocks Moving Lower In Thursday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Why Intel Shares Are Trading Higher By Over 10%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
Anaptys Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
From AnaptysBio, Inc.
Via GlobeNewswire
News headline image
Anaptys Announces Participation in March Investor Conferences
From AnaptysBio, Inc.
Via GlobeNewswire
News headline image
Gilead Sciences, Upstart, Mercury General, Confluent And Other Big Stocks Moving Higher On Wednesday ↗
 
Via Benzinga
News headline image
AnaptysBio Whipsaws On Promising Results In Rheumatoid Arthritis Treatment ↗
AnaptysBio stock whipsawed Wednesday despite promising results for its experimental rheumatoid arthritis treatment. 
Via Investor's Business Daily
News headline image
Anaptys Announces Rosnilimab Achieved Positive Results in RA Phase 2b Trial and Highest Ever Reported CDAI LDA Response Over 6 Months
From AnaptysBio, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Why Upstart Shares Are Trading Higher By Over 25%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
Anaptys to Announce Top-line Data from Phase 2b Trial of Rosnilimab, a PD-1 Depleter and Agonist, in Rheumatoid Arthritis on Feb. 12, 2025
From AnaptysBio, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.